ArticleCell communication and signaling : CCS2026
Opposing effects of Rho-associated coiled-coil kinase 1 (ROCK1) and ROCK2 in TGF-β-SMAD signaling.
Article in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTransforming growth factor-β (TGF-β) signals through type I and type II kinase-associated transmembrane receptors to activate both SMAD-dependent and SMAD-independent pathways, including the Rho/ROCK axis with its effectors ROCK1 and ROCK2. However, the role of ROCK isoforms in TGF-β-SMAD signaling in breast cancer cells, has not been elucidated.
methodsCAGA12-luciferase reporter assays were utilized to measure SMAD3/4-dependent transcription. Small-molecule kinase inhibitors and RNA interference-mediated gene silencing were provided for loss-of-function analyses. Immunoblotting, immunofluorescence staining, subcellular fractionation, in vitro kinase activity assay and mRNA expression assays were performed to gain mechanistic evidence. Mass spectrometry analysis coupled with co-immunoprecipitation assays examined the interaction between ROCK isoforms and other members of the TGF-ꞵ signaling pathway.
resultsROCK2 knockdown or treatment with the selective ROCK2 kinase inhibitor KD025 suppressed TGF-β-SMAD signaling, whereas ROCK1 knockdown produced the opposite effect. Overexpression studies revealed that ROCK1 inhibited, while ROCK2 enhanced, TGF-β-induced SMAD3/4-dependent transcriptional activity. These effects were reversed by expression of kinase-dead ROCK1 (K105R) or ROCK2 (K121D) mutants, and by treatment with ROCK inhibitors, demonstrating that the kinase activities of the two isoforms are required for their opposing functions. We further showed that ROCK1 and ROCK2 exhibit distinct subcellular localizations, and that SMAD3 interacts with ROCK1, but not with ROCK2. ROCK2 inhibition reduced phosphorylation at serine residues in the C-terminal (Ser423/425) and linker region (Ser204 and Ser208) of SMAD3, decreased nuclear accumulation of SMAD3 and SMAD4, and suppressed TGF-β-SMAD target gene expression. Functionally, ROCK1 depletion promoted cell proliferation and invasion in MDA-MB-231 cells, whereas ROCK2 depletion reduced proliferation and invasion.
conclusionsROCK1 and ROCK2 exert opposing, kinase-dependent effects on TGF-β-SMAD signaling and differentially affect breast cancer cell behaviours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.